tradingkey.logo
tradingkey.logo

Aclaris Therapeutics Completes Enrollment In Phase 2 Trial Of Bosakitug (Ati-045) In Atopic Dermatitis

ReutersMar 18, 2026 11:20 AM

- Aclaris Therapeutics Inc ACRS.O:

  • ACLARIS THERAPEUTICS COMPLETES ENROLLMENT IN PHASE 2 TRIAL OF BOSAKITUG (ATI-045) IN ATOPIC DERMATITIS

  • ACLARIS THERAPEUTICS INC - TOP LINE RESULTS FROM PHASE 2 TRIAL EXPECTED IN Q4 2026

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Recommended Articles

Tradingkey
KeyAI